An ad-free and cookie-free webpage by FactorPad
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Catalent Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how CTLT stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Pharmaceuticals: Other industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Catalent, Inc. operates as a holding company. The firm engages in the provision of delivery technologies and development solutions for drugs, biologics and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services. The Softgel Technologies segment formulates, develops and manufactures services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufactures services for blow-fill-seal unit doses, prefilled syringes, vials and cartridges, analytical development and testing services for large molecules, inhaled products for delivery via metered dose inhalers, dry powder inhalers and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
This is a new resource, spread the word, tell a friend